PMID- 33591615
OWN - NLM
STAT- MEDLINE
DCOM- 20210525
LR  - 20220531
IS  - 1529-8019 (Electronic)
IS  - 1396-0296 (Linking)
VI  - 34
IP  - 2
DP  - 2021 Mar
TI  - Autologous intralesional platelet rich plasma improves melasma.
PG  - e14881
LID - 10.1111/dth.14881 [doi]
AB  - Platelet rich plasma (PRP) is an upcoming interventional therapy for the 
      treatment of melasma. Its efficacy is due to the multiple growth factors present 
      in it which decrease melanogenesis by various signal transduction pathways. The 
      present study evaluated the efficacy of PRP as a standalone agent in treatment of 
      melasma. This is an open labeled prospective trial. Forty patients were given 
      intralesional PRP at once monthly interval. Three such PRP sessions were carried 
      out and the patients were followed up for 3 months. Assessment was done by 
      calculating the modified melasma area severity index score (mMASI) for each 
      patient. Patients were also asked to self-evaluate their improvement based on a 
      scale. There was an average 54.5% reduction in the mMASI score at the end of the 
      study. There was no relapse in any patient. This reduction was irrespective of 
      the skin type, gender, and type of melasma. Patients self-evaluation showed that 
      more than 90% of the patients were pleased or very pleased with the results. 
      There were no significant side effects. PRP appears to be a potential new therapy 
      with significant efficacy in improving pigmentation of melasma, standalone as 
      monotherapy.
CI  - (c) 2021 Wiley Periodicals LLC.
FAU - Tuknayat, Ankita
AU  - Tuknayat A
AUID- ORCID: 0000-0002-3110-000X
AD  - Department of Dermatology, Government Medical College and Hospital, Chandigarh, 
      India.
FAU - Thami, Gurvinder Pal
AU  - Thami GP
AD  - Department of Dermatology, Government Medical College and Hospital, Chandigarh, 
      India.
FAU - Bhalla, Mala
AU  - Bhalla M
AD  - Department of Dermatology, Government Medical College and Hospital, Chandigarh, 
      India.
FAU - Sandhu, Jasleen Kaur
AU  - Sandhu JK
AD  - Department of Dermatology, Government Medical College and Hospital, Chandigarh, 
      India.
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
DEP - 20210228
PL  - United States
TA  - Dermatol Ther
JT  - Dermatologic therapy
JID - 9700070
RN  - 0 (Intercellular Signaling Peptides and Proteins)
SB  - IM
MH  - Humans
MH  - Intercellular Signaling Peptides and Proteins
MH  - *Melanosis/diagnosis/therapy
MH  - *Platelet-Rich Plasma
MH  - Prospective Studies
MH  - Treatment Outcome
OTO - NOTNLM
OT  - epidermal growth factor
OT  - melasma
OT  - platelet rich plasma
OT  - transforming growth factor
EDAT- 2021/02/17 06:00
MHDA- 2021/05/26 06:00
CRDT- 2021/02/16 12:14
PHST- 2021/02/03 00:00 [revised]
PHST- 2020/11/26 00:00 [received]
PHST- 2021/02/06 00:00 [accepted]
PHST- 2021/02/17 06:00 [pubmed]
PHST- 2021/05/26 06:00 [medline]
PHST- 2021/02/16 12:14 [entrez]
AID - 10.1111/dth.14881 [doi]
PST - ppublish
SO  - Dermatol Ther. 2021 Mar;34(2):e14881. doi: 10.1111/dth.14881. Epub 2021 Feb 28.